MTOR and tuberous sclerosis: Given the prevalence of FAs and the psychosocial challenges they impose, this case underscores the broader therapeutic potential of systemic mTOR inhibition, suggesting that everolimus may contribute to improved physical and neurodevelopmental outcomes in TSC.